Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Inclusion Criteria: 1. Men and women, 18-75 years of age; 2. Participant with a histologically or cytologically confirmed solid tumor receiving treatment with chemotherapeutic agents; 3. Participant experienced thrombocytopenia and chemotherapy delay; 4. ECOG performance status 0-1; 5. Adequate Liver function; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3.0 x ULN for participants without liver metastases or 5.0 x ULN for participant with liver metastases); 6. Adequate renal function; serum creatinine \< 1.5 x ULN or eGFR≤60 ml/min（Cockcroft-Gault） Exclusion Criteria: 1. Participant has any history of hematologic diseases other than chemotherapy-induced thrombocytopenia; 2. Participant has serious bleeding symptoms; 3. History of allergy to the study drug; 4. Participant with HIV; 5. Pregnant or lactating women; 6. Participant has received any experimental therapy within 4 weeks prior to screening 7. Other conditions that may affect participant's safety or trial evaluations per investigator's discretion